Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06025331

Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?

The goal of this clinical trial is to compare two different types of reverse shoulder replacements. Researchers will compare a conventional reverse shoulder replacement with a lateralized reverse shoulder replacement to see if there is a difference in how well the patients function after two years.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Arthroplasty, Replacement, Shoulder Shoulder Osteoarthritis

Age range

45 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sykehuset Telemark HF, Skien, Telemark, Norway

Loading trial locations.

About this study

Many studies have showed pain relief and improvement in shoulder function following reverse shoulder arthroplasty (RSA), but medialization of the centre of rotation (COR) in RSA may cause complications like limited range of motion (ROM), luxation of the prosthesis, and scapular notching, where the lower part of the scapular neck becomes eroded due to impingement against the humeral component. Joint centre lateralization with a bone transplant placed underneath the glenoid component (BIO-RSA) was introduced to maximize ROM in the prosthetic joint, increase stability and to prevent scapular notching. In recent years it has been claimed that lateralization of the COR with BIO-RSA decreases the risk of the aforementioned complication, but no consensus on when or how to lateralize the COR exists as of today. This knowledge will also be of critical importance when it comes to decision making on how these patients are best treated. Results from this research project is expected to have a significant impact on how these patients are treated in the future, both nationally and internationally.

The purpose of this study is to compare functional results between patients with bony increased offset-reversed shoulder arthroplasty (BIO-RSA) and conventional reverse shoulder arthroplasty (RSA) to investigate if lateralization of the glenosphere yields superior outcomes and fewer complications after 2 years.

This multicenter study will include 130 patients in 4 hospitals scheduled for RSA. Patients will be asked to participate in a blinded RCT, where they are randomly assigned to either BIO-RSA or conventional RSA. Functional results will be measured primarily by the patient-reported outcome measure Western Ontario Osteoarthritis Shoulder (WOOS), but they will also be examined by a physiotherapist and CT imagery will be assessed by a radiologist.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eligible for primary RSA due to OA, massive RC tear, failed RC repair or post-instability osteoarthritis
  • Able to read or write Norwegian

Exclusion criteria

  • Severe osteoporosis
  • Osteonecrosis of the humeral head
  • Dementia
  • Poor deltoid function
  • Revision surgery
  • ASA IV
  • Suspected chronic infection
  • Acute fracture

Treatment and study plan

BIO-RSA

Procedure

Bony increased offset-reversed shoulder arthroplasty(BIO-RSA) will be performed.

Other names: Bony increased offset-reversed shoulder arthroplasty

RSA

Procedure

Conventional reversed shoulder arthroplasty(RSA) will be performed.

Other names: Reverse shoulder arthroplasty

Primary outcomes

  1. Change in WOOS index from baseline to 24 months postoperatively.

    Time frame: Before randomization, 24 months postoperatively. Also measured 3 and 12 months postoperatively. Change after 24 months will be the primary outcome.

    The Western Ontario Osteoarthritis of the Shoulder (WOOS) index is a patient-reported, disease-specific questionnaire for the measurement of the quality-of-life in patients with osteoarthritis.

    There are 19 questions divided into four domains: Physical symptoms, sports and work, lifestyle and emotions. Each question is answered on a visual analogue scale ranging from 0 to 100. The overall score ranges from 0 to 1900, with 1900 being the worst. For ease of interpretation, the scores are often converted to a percentage of the maximum score.

Secondary outcomes

  1. Change in EuroQol-5 from baseline to 24 months postoperatively.

    Time frame: Before randomization, 3, 12 and 24 months postoperatively.

    The widely used EuroQol-5 (EQ-5D-5L) will be used to measure health-related quality of life.

    The EQ5D-5L consists of two parts: A descriptive system (Mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and the EQ-VAS that record patients self-rated health on a visual analog scale that range from 0 -100, higher levels indicate better self-rated health.

    The descriptive system can be converted to a single summary index number where lower levels indicate poorer health related quality of life.

  2. CT scan

    Time frame: Before randomization, 3, 12 and 24 months postoperatively.

    Assessment of bone transplant integration and fixation of the glenoid implant.

  3. Change in Constant-Murley Score from baseline to 24 months postoperatively.

    Time frame: Before randomization, 3, 12 and 24 months postoperatively.

    The Constant-Murley Score (CMS) is a multi-item functional scale assessing pain, ADL, ROM and strength of the affected shoulder. Its score ranges from 0 to 100 points, representing worst and best shoulder function, respectively.

    The test is divided into subjective and objective components. Two subjective: pain and activities of daily living (ADL) and two objective: range of motion (ROM) and strength. The subjective components can receive up to 35 points and the objective 65.

    Pain and ADL are answered by the patient; ROM and strength require a physical evaluation and are answered by the physiotherapist.

  4. Change in range of motion from baseline to 24 months postoperatively.

    Time frame: Before randomization, 3, 12 and 24 months postoperatively.

    The patient's active and passive range of motion (ROM) in the affected shoulder will be measured by an experienced physiotherapist with a long-legged goniometer. The directions measured will be flexion, abduction, external rotation and internal rotation, measured in degrees and/or physical landmarks.

  5. Change in Subjective Shoulder Value from baseline to 24 months postoperatively.

    Time frame: Before randomization, 3, 12 and 24 months postoperatively.

    The Subjective Shoulder Value (SSV) score is defined as the subjective evaluation by the patient of shoulder function, expressed as a percentage of an entirely normal shoulder, which would score 100%.

  6. Anchor question 1

    Time frame: Before randomization, 3, 12 and 24 months postoperatively.

    This anchor question is asked to help determine Patient Acceptable Symptom State (PASS).

    PASS "Considering all daily activities that involves your operated shoulder, your level of pain and degree of function, how satisfied are you with the condition of your shoulder is right now?" Alternatives: Satisfied/somewhat satisfied/Neither satisfied or unsatisfied/somewhat unsatisfied/Unsatisfied

  7. Anchor question 2

    Time frame: 3, 12 and 24 months postoperatively.

    This anchor question is asked to help determine Minimal Important Difference (MID) and Substantial Clinical Benefit (SCB).

    "Think of all the ways your operated shoulder has affected you the last week. Since your surgery, has there been any change in the condition of your shoulder that you would consider important or meaningful to you?" Alternatives: Much better/moderately better/a bit better/no change/a bit worse/moderately worse/Much worse.

Study contacts

Contact information is provided by the study sponsor or research team.

Hanne Fuglø, MPTh

CONTACT

[email protected]

+4790524172

Kjersti Kaul Jenssen, PhD

CONTACT

[email protected]

+4790200650

Sponsors and collaborators

Lead sponsor

Lovisenberg Diakonale Hospital

Other

Collaborators

  • Haukeland University Hospital
  • Sykehuset Telemark
  • University Hospital, Akershus

Registry information

Official study title

From Cuff Arthropathy to Reverse Shoulder Arthroplasty - a Multicentre Randomized Control Trial (Study 1: Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?).

Acronym: CARS-1

Important dates

Study start
2023
Primary completion
2033
Study completion
2033
First posted
Sep 6, 2023
Registry last updated
Nov 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.